| 8:00 |
Networking Breakfast And Registration |
|
| 9:00 |
Chairperson’s Opening Remarks
 |
Jessica Hunt
VP Business Development
Gerson Lehrman Group |
 |
|
|
| 9:15 |
Opening Panel Discussion: Global Licensing Deals And The
Differing Challenges From Various Countries
 |
Christopher Seaton
Senior Vice President, Global Transactions
Bayer
Schering Pharmaceuticals |
 |
 |
Mark Miller
Senior Director of Corporate Business Development
Eli Lilly |
 |
 |
Steve Xanthoudakis
Director, Licensing and External Research
Merck |
 |
Many companies in today’s market are global, or are expanding their
reach to become global, but how do you effectively form profitable
partnerships overseas, and where do you begin to search? This panel
discussion will:
- Verify best practices from past experiences to enable future growth
potential
- Dig deeper into proven methods for identifying profitable
partnerships
- Benchmark past efforts to improve on future partnering
opportunities
|
|
| 10:00 |
Case Study: Global Partnering Challenges: A Small Biotech’s
Perspective
 |
David Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals LLC |
 |
Diffusion Pharmaceuticals LLC is a small, clinical-stage company developing small-molecule drugs for the treatment of hypoxic conditions, including cardiovascular diseases and the radiosensitization of hypoxic cancerous tumors. Diffusion’s management believes that its technology’s novel mechanism of action provides a platform – and its lead molecule provides near-term opportunity – to address unmet medical needs affecting millions of patients in billion-dollar markets. However, the Company’s potential and aspirations exceed its current available resources. Partnership with a major international pharmaceutical company is the preferred route to success. So its challenge is, ‘How does a small company with a big idea rise above the competitive crowd to attract the attention and win the support of a major international company?” |
|
| 10:40 |
Morning Refreshment Break And Networking Opportunity |
|
| 11:25 |
Case Study: The $8.8 Billion Acquisition of Millennium
Pharmaceuticals By Japan’s Takeda
 |
Catherine Sazdanoff
Vice President, Global Licensing
Takeda
Pharmaceuticals North America, Inc. |
 |
 |
Anna Protopapas
Senior Vice President of Corporate Development
Millennium Pharmaceuticals |
 |
This case study will discuss the deal from each side’s perspective, going from the strategic considerations that led to the idea, to the developing evaluations and steps that led to the negotiations, to the due diligence experience, the deal signing and closing, and the status of the relationship today. What was in it for Takeda? For Millennium? How did the two companies get comfortable with the idea? What was the internal process? Have things worked out the way each side thought they would? What “lessons learned” were captured? |
|
| 12:05 |
Lunch For All Attendees |
|
| 1:35 |
Global Partnering Roundtable Discussions
Hear from biotech companies in the rising countries within the life
sciences industry during these Roundtable Discussions focused on
identifying the most promising partnering opportunities within
emerging markets across the globe. These targeted discussions will
be focused on enabling enhanced networking opportunities specific
to the goals of your company.
Table 1 - Europe
 |
Kia Motesharei
Vice President, Business
Development
Genfit |
 |
Table 2 - Canada
| |
Sanj Singh
CEO
Ade Therapeutics |
|
Table 3 - India
Table 4 - Asia |
|
| 2:45 |
Afternoon Refreshment Break And Networking Opportunity |
|
| 3:30 |
Case Study: Merck’s Partnerships In India
 |
Reid Leonard
Vice President, External Licensing and Business
Development
Merck |
|
Recently, Merck has developed a global scouting network to identify
and develop unconventional deals with Indian Biotechnology
companies. This case study will discuss the risk sharing model involved in the identification process, as well as their partnering
selection capabilities and criteria vs. pipeline based models allowing
them to work on more projects for the same amount of funding.
|
|
| 4:10 |
Closing Discussion: Global Patent & Regulatory Strategies
 |
Mary Till
Legal Advisor, Office of Patent Legal Administration
United States Patent and Trademark Office |
|
| |
John Engel
Partner
Engel & Novit |
|
 |
Len Smith
Senior Intellectual Property Counsel
Novo Nordisk |
 |
Patent and regulatory strategies are more prevalent in the issues of today’s market than ever before. Understanding ownership issues which can arise in patent procurement processes, such as joint research agreements/103(c) and shield/terminal disclaimers, etc. is critical for business development to be involved in. Understanding how the life science industry deals with, not only FDA, but also the Centers for Medicare and Medicaid Services can help build better business operations to ultimately maintain a flourishing pipeline.
|
|
| 5:00 |
Welcome Reception On The Terrace
Hosted by Abbott Laboratories |
 |
